• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Nordic Nanovector Announces Changes to the Board of Directors and Notice of Extraordinary General Meeting

    Chelsea Pratt
    Sep. 21, 2016 01:58AM PST
    Biotech Investing

    Renee Tannenbaum has informed Nordic Nanovector ASA (“Company”) of her resignation from the board of directors for personal reasons. The board of directors wishes to thank Renee Tannenbaum for her contribution during the period she has served as a board member. The nomination committee proposes that Renee Tannenbaum is replaced by Joanna Horobin and the Company has today called for an extraordinary general meeting to be held on 12 October 2016. The notice of the extraordinary general meeting and the nomination committee’s proposal are attached.

    Renee Tannenbaum has informed Nordic Nanovector ASA (“Company”) of her resignation from the board of directors for personal reasons. The board of directors wishes to thank Renee Tannenbaum for her contribution during the period she has served as a board member. The nomination committee proposes that Renee Tannenbaum is replaced by Joanna Horobin and the Company has today called for an extraordinary general meeting to be held on 12 October 2016. The notice of the extraordinary general meeting and the nomination committee’s proposal are attached.
    This information is disclosed in accordance with the Norwegian
    Securities Trading Act Section 5-12.
    About Nordic Nanovector:
    Nordic Nanovector is a biotech company focusing on the development and
    commercialisation of novel targeted therapeutics in haematology and
    oncology. The Company’s lead clinical-stage product opportunity is
    Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates
    (ARC) designed to improve upon and complement current options for the
    treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
    substantial unmet medical need and orphan drug opportunities,
    representing a growing market worth over $12 billion by 2018.
    Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab
    (previously referred to as HH1), conjugated to a low intensity
    radionuclide (lutetium-177). The preliminary data has shown promising
    efficacy and safety profile in an ongoing Phase 1/2 study in a
    difficult-to-treat NHL patient population. The Company is aiming at
    developing Betalutin® for the treatment of major types of NHL with first
    regulatory submission anticipated in 1H 2019.
    Nordic Nanovector intends to retain marketing rights and to actively
    participate in the commercialisation of Betalutin® in core markets,
    while exploring potential distribution agreements in selected
    geographies. The Company is committed to developing its ARC pipeline to
    treat multiple selected cancer indications.
    Further information about the Company can be found at www.nordicnanovector.com
    This information was brought to you by Cision https://news.cision.com

    orphan drugboard of directorsnomination committeenordic nanovector
    The Conversation (0)
    Go Deeper
    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×